Posts by Rebecca Suk Heist, MD, MPH
Study Provides Insight Into Overcoming Acquired Resistance to KRAS-G12C Inhibitors
Researchers at the Massachusetts General Hospital Cancer Center and colleagues have identified mutations that make lung cancer resistant to adagrasib and other KRAS-G12C inhibitors. Their findings provide clues to designing next-generation inhibitors and combination regimens.
Capmatinib Benefits Adults with Advanced NSCLC and MET Exon 14 Skipping Mutation
Rebecca S. Heist, MD, MPH, and colleagues led the phase 2 GEOMETRY mono-1 trial, the basis for FDA approval of capmatinib, a highly specific new MET inhibitor for treatment of adults with MET exon 14–mutated metastatic non–small-cell lung cancer.
Physician in the Division of Hematology/Oncology, Mass General Cancer Center